VJHemOnc is committed to improving our service to you

ISA 2020 | TOURMALINE-AL1: ixazomib and dexamethasone for AL amyloidosis

VJHemOnc is committed to improving our service to you

Giampaolo Merlini

Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, discusses the Phase III TOURMALINE-AL1 trial (NCT01659658), a study that compares the efficacy of ixazomib and dexamethasone versus physician’s choice in relapsed or refractory systemic light-chain (AL) amyloidosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter